Updates as of February 2, 2022:

• With the predominance of the Omicron variant, National Institutes of Health (NIH) treatment recommendations, and recent data showing that bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) are not effective against the Omicron variant, the FDA has revised the EUAs for these two monoclonal antibodies. Bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) are currently not authorized for use in any U.S. states, territories, and jurisdictions. 

With the rapid spread of the Omicron variant in mid-December 2021 and data showing that casirivimab/Imdevimab (REGEN-COV) is not effective in patients infected with this variant, the NIH updated their treatment guidelines to recommend against the use of casirivimab/Imdevimab (REGEN-COV) on January 19, 2022.

On January 24, 2022, the FDA revised the EUA for casirivimab/Imdevimab (REGEN-COV) to limit its use. Casirivimab/Imdevimab (REGEN-COV) is not authorized for use in any U.S. states, territories, and jurisdictions at this time.

HHS has paused allocation of casirivimab/Imdevimab (REGEN-COV), and, at this time, CDPH is not distributing casirivimab/Imdevimab (REGEN-COV) to jursidictions. This product is not available and cannot be ordered.

If future variants are found to be susceptible to casirivimab/Imdevimab (REGEN-COV), this product may become available in the future